Low dose metronomic chemotherapy with cyclophosphamide and piroxicam for the management of canine mammary neoplasms

dc.contributor.authorSowbharenya, C
dc.contributor.authorDharmaceelan, S
dc.contributor.authorSubramanian, M
dc.contributor.authorKumaresan, A
dc.contributor.authorTANUVAS
dc.date.accessioned2019-03-18T12:04:28Z
dc.date.available2019-03-18T12:04:28Z
dc.date.issued2018
dc.descriptionTNV_ IJAR_2018_1-5en_US
dc.description.abstractA clinical research was undertaken to evaluate the effect of low dose metronomic (LDM) chemotherapy in 18 clinical cases of canine mammary neoplasms (CMN). The cases were randomly divided into three groups each consisting of six animals. Group I was subjected to LDM therapy with cyclophosphamide @ 10 mg/m2 and piroxicam @ 0.3 mg/kg per os for a period of eight weeks pre operatively on alternate days. Group II was subjected to mere surgical excision alone. Group III was subjected to LDM therapy from 10th day following tumour excision for a period of eight weeks as in group I. Effect of LDM therapy was evaluated based on regression of tumour size and the disease free interval. The haematological and biochemical values were evaluated. Among the three groups, Group I showed progressive regression in the disease free interval improving the quality of life.en_US
dc.identifier.urihttp://krishikosh.egranth.ac.in/handle/1/5810098890
dc.keywordsCanine mammary neoplasms, Cyclophosphamide, Low dose metronomic chemotherapy, Piroxicam.en_US
dc.language.isoenen_US
dc.pages1-5en_US
dc.subjectVeterinary Scienceen_US
dc.titleLow dose metronomic chemotherapy with cyclophosphamide and piroxicam for the management of canine mammary neoplasmsen_US
dc.title.alternativeIndian Journal of Animal Researchen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
TNV_ IJAR_2018_1-5.pdf
Size:
348.1 KB
Format:
Adobe Portable Document Format
Description:
TNV_ IJAR_2018_1-5
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: